Loading
Latest filing published 24 Feb 2026 for Caribou Biosciences, Inc.. Read the official filing
Across 2 buy signals with a settled T+90 return. Return basis: close on the day after publication.
Barbara G. Mcclung (senior executive) discloses dealings in Caribou Biosciences, Inc. to SEC (Form 4). In total, 6 filings cover trades dated from 20 October 2021 to 20 February 2026.
Every open-market trade on record is a purchase: 2 purchases worth €21k, and no sale. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. Other entries cover 3 share grants and 1 option exercise.
Most recently, on 24 February 2026, the filings show a share grant in Caribou Biosciences, Inc. The latest purchase dates back some time: it was published 1,775 days ago, on 8 December 2021. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 1 day. Section 16 rules allow two business days to file each Form 4. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
6 of 6 declarations